Short Interest Watching: BOHAI PHARMACEUTICAL (OTCMKTS:BOPH) Could Improve Your Long Portfolio After Less Shorts Reported

November 28, 2016 - By Linda Rogers   ·   0 Comments

Short Interest Watching: BOHAI PHARMACEUTICAL (OTCMKTS:BOPH) Could Improve Your Long Portfolio After Less Shorts Reported

The stock of BOHAI PHARMACEUTICAL (OTCMKTS:BOPH) registered a decrease of 84.85% in short interest. BOPH’s total short interest was 500 shares in November as published by FINRA. Its down 84.85% from 3,300 shares, reported previously. The stock closed at $0.42 during the last session. It is down 2.44% since April 25, 2016 and is uptrending. It has underperformed by 3.57% the S&P500.

Bohai Pharmaceuticals Group, Inc. is a maker and marketer of herb pharmaceutical formulations based on traditional Chinese medicine . The company has a market cap of $7.03 million. The Company’s medicines address rheumatoid arthritis, viral infections, gynecological diseases, cardio vascular issues and respiratory diseases. It has a 0.38 P/E ratio. The Firm produces seven varieties of traditional Chinese herbal medicines in seven delivery systems: tablets, granules, capsules, formulations, concentrated powder, tincture and medicinal wine.

BOPH Company Profile

Bohai Pharmaceuticals Group, Inc., incorporated on January 9, 2008, is a maker and marketer of herb pharmaceutical formulations based on traditional Chinese medicine (TCM). The Company’s medicines address rheumatoid arthritis, viral infections, gynecological diseases, cardio vascular issues and respiratory diseases. The Firm produces seven varieties of traditional Chinese herbal medicines in seven delivery systems: tablets, granules, capsules, formulations, concentrated powder, tincture and medicinal wine. The Company’s drugs are sold to approximately 2,000 hospitals, 17,000 rural hospitals/clinics and 2,900 retail pharmacies.

More notable recent Bohai Pharmaceuticals Group, Inc. (OTCMKTS:BOPH) news were published by: Seekingalpha.com which released: “What Have We Learned From Bohai Pharmaceuticals? (BOPH)” on May 16, 2015, also Law360.com with their article: “Bohai Pharma Hit With Suit Claiming Securities Shenanigans” published on June 09, 2015, Law360.com published: “Dacheng Parts With Chinese Pharma Client In $6M Suit” on February 20, 2016. More interesting news about Bohai Pharmaceuticals Group, Inc. (OTCMKTS:BOPH) were released by: Law360.com and their article: “Euro Pacific Fights Bid For Arbitration In $6M Contract Row” published on November 18, 2015 as well as Investorideas.com‘s news article titled: “Biotech Stock Directory Update” with publication date: August 14, 2014.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Linda Rogers


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>